Abstract
Alzheimer’s disease (AD), a chronic neurodegenerative disease, is the most common form of dementia that causes cognitive function impairment, including memory, thinking, and behavioral changes that ultimately lead to death. The overactivation of GSK-3, an enzyme from the proline/serine Ki NS family, has been associated with hyper-phosphorylation of tau proteins. The self- -assembly of hyper-phosphorylated tau proteins to form tangles of straight and helical filaments is known to be involved in AD. Therefore, GSK-3 has been considered a potential target of novel drug discovery for AD treatment. Research on the development of GSK-3 inhibitors has received enormous attention from the vast scientific community because they are targeted for AD and other diseases, including type 2 diabetes, cancers, stroke, Parkinson’s disease and bipolar disorder. Various drugs of both synthetic and natural origins have been designed to inhibit GSK-3 activity. However, there is a need to develop novel drug candidates that can selectively inhibit GSK-3. Hence, this review summarizes the potential of GSK-3 inhibitors for AD therapy and discusses the structure- activity relationship of current drug molecules and the potential problems associated with them.
Keywords: Alzheimer's disease, GSK-3, GSK-3 inhibitors, Tau, β-amyloid, neurodegenerative diseases, protein kinase.
Current Drug Targets
Title:GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Volume: 22 Issue: 15
Author(s): Dilipkumar Pal, Souvik Mukherjee, In-Ho Song and Satish B. Nimse*
Affiliation:
- Institute of Applied Chemistry and Department of Chemistry, Hallym University, Chuncheon 200702,Korea
Keywords: Alzheimer's disease, GSK-3, GSK-3 inhibitors, Tau, β-amyloid, neurodegenerative diseases, protein kinase.
Abstract: Alzheimer’s disease (AD), a chronic neurodegenerative disease, is the most common form of dementia that causes cognitive function impairment, including memory, thinking, and behavioral changes that ultimately lead to death. The overactivation of GSK-3, an enzyme from the proline/serine Ki NS family, has been associated with hyper-phosphorylation of tau proteins. The self- -assembly of hyper-phosphorylated tau proteins to form tangles of straight and helical filaments is known to be involved in AD. Therefore, GSK-3 has been considered a potential target of novel drug discovery for AD treatment. Research on the development of GSK-3 inhibitors has received enormous attention from the vast scientific community because they are targeted for AD and other diseases, including type 2 diabetes, cancers, stroke, Parkinson’s disease and bipolar disorder. Various drugs of both synthetic and natural origins have been designed to inhibit GSK-3 activity. However, there is a need to develop novel drug candidates that can selectively inhibit GSK-3. Hence, this review summarizes the potential of GSK-3 inhibitors for AD therapy and discusses the structure- activity relationship of current drug molecules and the potential problems associated with them.
Export Options
About this article
Cite this article as:
Pal Dilipkumar , Mukherjee Souvik , Song In-Ho and Nimse B. Satish*, GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment, Current Drug Targets 2021; 22 (15) . https://dx.doi.org/10.2174/1389450122666210114095307
DOI https://dx.doi.org/10.2174/1389450122666210114095307 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Procedural (Conscious) Sedation and Analgesia in Emergency Setting: How to
Choose Agents?
Current Pharmaceutical Design The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease
Current Pharmaceutical Design A Conceptual Framework for Research on Cognitive Impairment with no Dementia in Memory Clinic
Current Alzheimer Research Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases
Current Drug Therapy Conventional (Continuous) EEG Monitoring in the NICU
Current Pediatric Reviews Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research Cerebral Vascular Aging: Extending the Concept of Pulse Wave Encephalopathy Through Capillaries to the Cerebral Veins
Current Aging Science Aquaporin and Blood Brain Barrier
Current Neuropharmacology Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Microdialysis in Neurointensive Care
Current Pharmaceutical Design Plasma Metabolic Profiling of Mild Cognitive Impairment and Alzheimer's Disease Using Liquid Chromatography/Mass Spectrometry
Central Nervous System Agents in Medicinal Chemistry Papillary Tumor of the Pineal Region with Parinaud Syndrome: A Case Report
Current Medical Imaging Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets
Current Neuropharmacology Glucose Levels and Outcome After Primary Intraventricular Hemorrhage
Current Neurovascular Research The Therapeutic Application of Hydrogen in Cancer: The Potential and Challenges
Current Pharmaceutical Design Magnetic Resonance Elastography
Current Medical Imaging Lesions and Dysfunctions of the Nucleus Basalis as Alzheimers Disease Models: General and Critical Overview and Analysis of the Long-Term Changes in Several Excitotoxic Models
Current Alzheimer Research